Cytokinetics CEO defends Royalty Pharma deal: 'That narrative was hijacked'

Max Gelman

Senior Editor

Cytokinetics CEO Robert Blum blamed investor frustration over a deal with Royalty Pharma on a “hijacked” narrative that the company would be better off selling …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cytokinetics CEO defends Royalty Pharma deal: 'That narrative was hijacked'

Max Gelman

Senior Editor

Sign up to read this article for free.

Autoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling early-stage results

Gilead cancer drug magrolimab showed worrying trends around death

Stephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan closes first $500M+ biotech fund

Rare pediatric disease vouchers face uncertain future after September

With new data, AstraZeneca makes the case for its BTK inhibitor in a first-line setting

De-risking the patient journey in cell therapies: Six key considerations

Cy­to­ki­net­ics CEO de­fends Roy­al­ty Phar­ma deal: 'That nar­ra­tive was hi­jacked'

Max Gelman

Senior Editor

Sign up to read this article for free.

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

Rare pe­di­atric dis­ease vouch­ers face un­cer­tain fu­ture af­ter Sep­tem­ber

With new da­ta, As­traZeneca makes the case for its BTK in­hibitor in a first-line set­ting

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

Cytokinetics CEO defends Royalty Pharma deal: 'That narrative was hijacked'

Autoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling early-stage results

Gilead cancer drug magrolimab showed worrying trends around death

Stephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan closes first $500M+ biotech fund

Rare pediatric disease vouchers face uncertain future after September

With new data, AstraZeneca makes the case for its BTK inhibitor in a first-line setting

De-risking the patient journey in cell therapies: Six key considerations